

ANDREW BRADBURY

The Second Annual
IBC International Conference on

ANTIBODY ENGINEERING

December 16-18, 1991 • Omni San Diego Hotel • San Diego, CA

Organized by:



International Business Communications

IBC USA Conferences Inc. • 8 Pleasant Street, Bldg. D • South Natick, Mass. 01760
(508) 650-4700


WELCOME

IBC USA Conferences welcomes you to Antibody Engineering.

No meeting is truly successful if it simply serves the purpose of transferring information. We hope the interactions between the speakers and the audience will help you gain insights that you can use today.

We strongly encourage your participation throughout the conference and have allowed time for you to pose questions to the speakers. Ample time for informal interactions has also been allocated throughout the day. These encounters will complement both the speaker presentations and the written material.


Our staff members are available throughout the conference to provide assistance. Please do not hesitate to call on us. We thank you for joining us!




Phillips Kuhl
Conference Director



Gail Scho
Conference Manager



Christine Andrews
Conference Coordinator



Susan Hamano
Conference Coordinator

IBC USA Conferences

20. 5A. 10A / 13



(20. 4. 13)

Note: Delegates are required to wear their badges at all times. Those without their badges will not be admitted.

ANTIBODY ENGINEERING

Schedule of Events

Welcome & Introduction • Speaker Contacts • Speaker Presentations

Sunday, December 15, 1991

8:30 p.m.-10:30 p.m. *Early Registration*

Monday, December 16, 1991

7:00 a.m.-8:30 a.m. *Registration, Poster Set-up & Coffee*

ENGINEERING TO AVOID HAMA

- 8:30 **CHAIRMAN'S OPENING REMARKS**
Dr. Sherie L. Morrison, *Professor of Microbiology and Molecular Genetics, Member of the Molecular Biology Institute, UCLA*
- 8:35 **HUMANIZED ANTIBODIES FOR THERAPY**
Dr. Cary Queen, *Vice President, Research, Protein Design Labs, Inc.*
- 9:05 **FRAMEWORK CHOICE & RESIDUE SUBSTITUTION FOR HUMANIZED VENEERED ANTIBODIES**
Dr. George E. Mark III, *Director, Cellular & Molecular Biology, Merck Sharp & Dohme Research Laboratories*
- 9:35 **USE OF A VACCINIA/T7 SYSTEM TO RAPIDLY ANALYZE HUMANIZED & OTHER ENGINEERED SINGLE-CHAIN FV'S**
Dr. Syd Johnson, *Research Scientist, MedImmune, Inc.*
- 10:05 *Refreshment Break & Posters*
- 10:45 **FUNCTIONAL ANALYSIS OF HUMANIZED OKT3 & OKT4A**
Dr. Robert A. Zivln, *Principal Scientist, Biotech, R. W. Johnson Pharmaceutical Research Institute*
- 11:15 **BIOACTIVE PEPTIDE DESIGN BASED ON ANTIBODY HYPERVARIABLE REGION STRUCTURE**
Dr. William V. Williams, *Department of Medicine, University of Pennsylvania School of Medicine*
- 11:45 **ORAL PRESENTATION OF SELECTED POSTERS**
- 12:00 **PANEL DISCUSSION**
- 12:30 *Luncheon*

EXPRESSION & ENGINEERING

- 1:45 **CHAIRMAN'S REMARKS**
Dr. James D. Marks, *Research Scientist, Medical Research Council (U.K.)*
- 1:50 **ANTIBODY ENGINEERING BY ENZYMATIC INVERSE PCR**
Dr. Willem P. C. Stemmer, *Senior Research Scientist, Hybritech, Inc.*
- 2:20 **MAKING HUMAN ANTIBODIES USING PHAGE SELECTION**
Dr. James D. Marks

- 2:50 **IN VITRO AFFINITY MATURATION BY SITE DIRECTED MUTAGENESIS**
Dr. William D. Huse, *Chief Scientific Officer, IXSYS, Inc.*
- 3:20 *Refreshment Break & Posters*
- 4:00 **ANTIBODY ENGINEERING FOR MICROBIAL EXPRESSION & THERAPEUTIC USE**
Dr. Arnold H. Horwitz, *Director of Molecular Microbiology, XOMA Corporation*
- 4:30 **RECENT ADVANCES WITH CATALYTIC ANTIBODIES**
Dr. Mark A. Gallop, *Staff Scientist, Bioorganic Chemistry, Affymax Research Institute*
- 5:00 **ORAL PRESENTATION OF SELECTED POSTERS**
- 5:15 **PANEL DISCUSSION**
- 5:45 *Close of Day One*

Tuesday, December 17, 1991

- 7:30 *Coffee & Posters*

BI-SPECIFIC & BI-FUNCTIONAL

- 8:00 **CHAIRMAN'S REMARKS**
Dr. Sherie L. Morrison, *Professor of Microbiology and Molecular Genetics. Member of the Molecular Biology Institute. UCLA*
- 8:05 **OVERCOMING ANTIBODY BLOCKAGE USING BI-SPECIFIC ANTIBODIES**
Dr. Nathan B. Dinces, *Vice President, Medarex, Inc.*
- 8:35 **RESEARCH & CLINICAL EXPERIENCE WITH BI-SPECIFIC ANTIBODIES**
Dr. Joesph G. Major, *Senior Research Scientist, Hybritech, Incorporated*
- 9:05 **TARGETING CYTOTOXICITY WITH A BI-SPECIFIC ANTIBODY DIRECTED TO C-ERB-2 & HUMAN FC γ RECEPTOR III**
Dr. David B. Ring, *Senior Scientist, Director, Department of Immunology, Cetus Corporation*
- 9:35 *Refreshment Break & Posters*
- 10:15 **PRODUCTION OF A SINGLE-CHAIN BI-SPECIFIC ANTIBODY**
Dr. Andrew J. T. George, *Experimental Immunology Branch, National Cancer Institute, National Institutes of Health*
- 10:45 **GENETIC ENGINEERING OF ANTIBODIES FOR NOVEL FUNCTIONS**
Dr. Sherie L. Morrison
- 11:15 **ORAL PRESENTATION OF SELECTED POSTERS**
- 11:30 **PANEL DISCUSSION**
- 12:00 *Lunch Break*

HUMAN MONOCLONALS

- 1:15 **CHAIRMAN'S REMARKS**
Dr. Mark C. Glassy, *Editor-in-Chief, Human Antibodies and Hybridomas and President, Sci-Clone, Inc.*
- 1:20 **HUMAN MONOCLONAL IMAGINEERING**
Dr. Mark C. Glassy
- 1:50 **HUMAN ANTIBODIES BY REPERTOIRE CLONING**
Dr. Carlos F. Barbas, *Assistant Professor, Scripps Research Institute*

- 2:20 **PRODUCTION & APPLICATION OF HUMAN MONOCLONAL ANTIBODIES**
Dr. S. M. Iwasa, *Research Manager, Biology Research Laboratories, Takeda Chemical Industries, Ltd.*
- 2:50 *Refreshment Break & Posters*
- 3:30 **IN VITRO IMMUNIZATION METHODS FOR PRODUCTION OF HUMAN IGG MONOCLONAL ANTIBODIES**
Dr. Paula Boerner, *Director of Cell Biology, IXSYS, Inc.*
- 4:00 **DEVELOPMENT OF A HUMAN IMMUNOGLOBULIN TRANSGENIC MOUSE**
Dr. Nils Lonberg, *Senior Scientist, GenPharm International*
- 4:30 **ORAL PRESENTATION OF SELECTED POSTERS**
- 4:45 **PANEL DISCUSSION**
- 5:15 **POSTERS**
- 6:00 *Cocktail Reception*
- 7:30 *Close of Day Two*

Wednesday, December 18, 1991

- 7:30 *Coffee & Posters*

CLINICAL EXPERIENCE

- 8:00 **CHAIRMAN'S REMARKS**
Dr. Albert F. LoBuglio, *Director, Comprehensive Cancer Center, Professor of Medicine, University of Alabama at Birmingham*
- 8:05 **PHARMACOKINETICS & IMMUNE RESPONSE OF MURINE & CHIMERIC ANTIBODIES**
Dr. Albert F. LoBuglio
- 8:35 **CLINICAL EXPERIENCE WITH THE L6 ANTI-CARCINOMA ANTIBODY**
Dr. Dale E. Yelton, *Scientist, Bristol-Myers Squibb Pharmaceutical Research Institute*
- 9:05 **CLINICAL RESULTS WITH CHIMERIC & HUMAN MONOCLONAL ANTIBODIES**
Dr. James N. Woody, *Senior Vice President, Centocor, Inc.*
- 9:35 *Refreshment Break and Posters*
- 10:15 **PATIENT RESPONSE TO CHIMERIC B72.3**
Dr. Terry S. Baker, *Principal Scientist, Celltech, Ltd.*
- 10:45 **INTERNAL IMAGE ANTIGENS AS THERAPEUTIC MODALITIES FOR CANCER & INFECTIOUS DISEASES**
Dr. Samuel D. Waksal, *President and CEO, ImClone Systems Inc.*
- 11:15 **ORAL PRESENTATION OF SELECTED POSTERS**
- 11:30 **PANEL DISCUSSION**
- 12:00 *Close of Conference*

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.